Search Results - "Panchapakesan, U."

The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose by Salheen, S.M., Panchapakesan, U., Pollock, C.A., Woodman, O.L.

“…The aim of the study was to investigate the effects of the DPP-4 inhibitors and GLP-1R agonist, exendin-4 on the mechanism(s) of endothelium-dependent…”
Get full text

The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells by Panchapakesan, U, Pollock, C A, Chen, X M

“…Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) are ligand-activated transcription factors that regulate cell growth, inflammation, lipid…”
Get more information

Recovery of pure red-cell aplasia secondary to antierythropoietin antibodies after cessation of recombinant human erythropoietin by Panchapakesan, U., Austin, S. K., Shafransky, A., Lawrence, J. A., Savdie, E.

“…We describe a patient with end‐stage renal failure (ESRF) who developed anti‐erythropoietin (anti‐EPO) antibodies and pure red‐cell aplasia (PRCA) after using…”
Get full text

PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose by Panchapakesan, U, Sumual, S, Pollock, C A, Chen, X

“…Peroxisome proliferator-activated receptor-gamma (PPARgamma) are ligand-activated transcription factors that regulate cell growth, inflammation, lipid…”
Get more information

Drug Insight: thiazolidinediones and diabetic nephropathy—relevance to renoprotection by Pollock, Carol A, Panchapakesan, Usha, Chen, Xin-Ming

“…Up to a third of people with diabetes mellitus suffer end-stage renal failure due to diabetic nephropathy. Strategies to delay progression of diabetic…”
Get full text

ANTI-ERYTHROPOEITIN ANTIBODIES AS A CAUSE OF PURE RED CELL APLASIA IN END STAGE RENAL FAILURE AFTER RECOMBINANT HUMAN ERYTHROPOEITIN THERAPY (rhuEPO) by U, Panchapakesan, Sk, Austin, Ja, Lawrence, A, Shafransky, E, Savdie

Get full text